Tyrosine Kinase Inhibitor Dosing Patterns in Elderly Patients with Chronic Myeloid Leukemia

ConclusionsDose reduction was observed in 65.9% of the patients at their last visit; except imatinib, TKI dose densities were < 50% of the recommended dose for the chronic phase. Therefore, the recommended TKI doses might be too high for elderly patients with CML.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research